Advancing Our
Pipeline
Leveraging computational biology and AI to deliver precision therapeutics targeting significant unmet medical needs with transformative potential.
Delivering Groundbreaking
Solutions for Patients
Orogen Therapeutics' mission is to deliver groundbreaking clinical solutions to patients with serious unmet medical needs. We are revolutionizing small-molecule drug discovery through our proprietary platform, which integrates DNA-encoded libraries (DEL), proprietary, target-specific FocusDEL™ with massive chemical diversity, virtual screening, and AI-driven computation.
This unique foundation empowers us to efficiently derive novel drug candidates across a broad range of target classes, focusing first and foremost on addressing patient needs.
We apply our patient-centered approach to discrete therapeutic area and clinical indication verticals, the first of which is developing small molecule alternatives to biological products in the immuno-inflammation (INI) space, with the goal of improving treatment accessibility and quality of life.
Small Molecule Alternatives To Biologics (SMABs)
Enter Orogen's first focus area: small molecule alternatives to biologics, with multiple hit series identified against a range of cytokine targets, and several candidates in lead optimization aimed at near-term lead selection. Our goal is to transform patient care through more accessible and convenient treatment options.
Treatments that Change Lives
A core emphasis for Orogen is in the immuno-inflammatory space. Our immuno-inflammation (INI) programs are designed to address the underlying causes of autoimmune and inflammatory disorders, potentially offering more effective treatments with fewer side effects than existing therapies.
Tackling immuno-inflammation at its core
Our drug discovery platform allows us to develop novel small molecule therapeutics targeting key proteins implicated in autoimmune and inflammatory disorders.
By addressing these disorders at their molecular roots, we aim to provide more targeted therapies that address the underlying causes rather than just treating symptoms.
- Targeting upstream pathways to address disease causes
- Addressing unmet needs in multiple therapeutic areas
- Creating orally available treatments for improved patient experience
Orogen Pipeline
Below is a snapshot of our current progress within the immuno-inflammation space.
| Target | Discovery Hit Lead Op DC / IND | Indications4 |
|---|---|---|
IL-171 | DC Cohort Backup Best-in-class potential | Skin (PP, HS) |
TNFα2 | Joint (RA) | |
TL1A3 | First-in-class potential | GI (IBD, CD) |
Additional targets (undisclosed) | B-cell, etc. |
- ¹ novel composition of matter family; patent pending
- ² potentially novel mechanism of action
- ³ no marketed products
⁴ Clinical indication abbreviations:
- PP – plaque psoriasis
- HS – hidradenitis suppurativa
- RA – rheumatoid arthritis
- IBD – inflammatory bowel disease
- CD – Crohn’s disease
Main asset, supported by repeatable engine.
The Future Beyond INI
While immuno-inflammation represents our initial strategic push, the power and versatility of the Orogen platform extend far beyond. We have additional areas of focus already underway and intend to continue expanding our pipeline to tackle other serious diseases where our unique approach can make a significant difference.
Cardiometabolic Diseases
Developing novel approaches to address underlying causes of major metabolic and cardiovascular disorders.
Oncology
Focusing on key cancer targets with high unmet medical need.
Neurological Disorders
Targeting neuroinflammatory pathways implicated in neurodegenerative diseases.
Expanding Our Horizons
Our proprietary platform is designed to be adaptable across multiple therapeutic areas, allowing us to efficiently address a wide range of diseases with significant unmet needs.
"Orogen is elevating new heights in drug discovery, integrating massive chemical libraries, target-specific screening, and AI-based computation to propel the generation of novel medicines."
Mark Pykett
CEO, Orogen Therapeutics